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Abstract 
 
Characteristics of patients with chronic rhinosinusitis who underwent 
endoscopic sinus surgery 
Author: Jeffry Mattar 
 
This study assessed the characteristics of patients with CRS, with or without nasal polyps, who 
underwent ESS as part of their treatment for sinonasal disease at the Department of ORL HNS, 
Sisters of Charity University Hospital in Zagreb and compared the results to other studies done 
on CRS patients. 
Patients who were operated during a year period of 2016 were audited. The data collected 
included demographic features of patients, risk factors exposure, diagnosis, and type of 
endoscopic surgical procedures which were performed to treat the sinonasal disease. The 
purpose of the study was to understand the characteristics of patients who need ESS as part of 
their treatment course. In total, 189 patients were included in the study. Of which, 67% of the 
participants (85 males and 46 females) are diagnosed with CRSwNP and 31% (30 males and 28 
females) are diagnosed with CRSsNP, 2% are diagnosed with CRS with tumor. In this study 13 
patients were in the age group of <18 years (6.8%), followed by 28 in the age group of 19-30 
(14.8%), 54 patients were in the age group of 31-45 (28.5%), 57 patients were in the age group 
of 46-60 (30%), and 37 patients were above 60 years (19.5%). The mean age for patients with 
CRSwNP was 49.2 and for the patients with CRSsNP was 38.7. The results showed that male 
gender was more associated with nasal polyps and that the frequencies of allergy, asthma, and 
aspirin sensitivity were significantly higher than for patients diagnosed with CRSsNP. Patients 
with CRSwNP tend to undergo more than one endoscopic procedure compared to patient without 
polyps. Septal deviation was more prevalent in the CRSsNP group (55%) when compared to 
CRSwNP (25.2%). The majority of the patients who underwent surgery had multiple sinuses 
involved (40%). Single-sinus operations were more common among ethmoid (17%) and maxillary 
(13%) sinuses. 
 
Key words: Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps, Nasal polyps, 
Endoscopic sinus surgery 
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Sažetak 
Značajke bolesnika s kroničnim rinosinusitisom liječenih 
endoskopskom sinusnom kirurgijom 
Autor: Jeffry Mattar 
U ovom istraživanju proučavaju se značajke pacijenata s dijagnozom kroničnog 
rinosinusitisa, od kojih neki imaju pridruženu nosnu polipozu, a liječeni su endoskopskom 
sinusnom kirurgijom na Klinici za otorinolaringologiju i kirurgiju glave i vrata u KBC Sestre 
milosrdnice u Zagrebu tijekom 2016. godine. 
Prikupljeni podaci uključuju demografske karakterisitke pacijenata, faktore rizika, dijagozu i 
vrstu endoskopske operacije koja je izvedena. Svrha ovog istraživanja je istražiti značajke 
pacijenata kojima je potrebna endoskopska operacija sinusa kao dio liječenja. U istraživanje 
je uključeno ukupno 189 pacijenata, od kojih je 67% (85 muškaraca i 46 žena) imalo 
dijagnozu kroničnog rinosinusitisa s nosnim polipima, a 31 % (30 muškaraca i 28 žena) imalo 
dijagnozu kroničnog rinusinusitisa bez nosnih polipa. Samo 2% pacijenata imalo je pridruženi 
tumor uz dijagnozu kroničnog rinosinusitisa. U ovom istraživanju 13 pacijenata nalazi su u 
dobnoj skupini mlađoj od 18 (6.8%), 28 pacijenata je u grupi od 19-30 (14.8%), 54 pacijenata 
u grupi od 31-45 (28.5%) godina, 57 njih nalazi se u grupi od 46-60 (30%) godina i 37 
pacijenata je starije od 60 godina (19,5%). Prosječna dob pacijenata s nosnim polipima je 
49.2, a onih bez polipa je 38.7. Rezultati su pokazali da je prisutnost polipa veća u muškog 
spola te da je učestalost polipa veća u pacijenata koji imaju astmu, alergije ili su preosjetljvi 
na aspirin. Pacijenti s polipima su češće operirani više puta u odnosu na pacijenete s 
kroničnim rinosinusitisom bez polipa. Prevalencija septalne devijacije je veća u pacijenata 
bez polipa (55%) u odnosu na pacijente s polipima (25.2%). Većina pacijenata koji su 
endoskopski operirani imali su bolest prisutnu u više sinusa, s time da je najčešće upala 
bila prisutna u etmoidnim (17%) i maksilarnim (13%) sinusima. 
. 
Ključne riječi: kronični rinosinusitis, kronični rinosinusitis s nosnim polipima, nosni polipi, 
endoskopska kirurgija sinusa  
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1. Introduction 
Rhinosinusitis, in its various forms, constitutes, one of the commonest conditions 
encountered in medicine and may present to a wide range of clinicians, including primary 
care, pulmonologists, allergists, otorhinolaryngologists, neurosurgeons and more, 
especially when complications occur. The introduction part of this paper will present the 
basics of rhinosinusitis disease, as well as explain its various types and subtypes, while 
concentrating on chronic cases, diagnosis and clinical severities. In addition to these, 
treatment modalities, in particular endoscopic sinus surgery will also be addressed. 
1.1. Rhinosinusitis 
Rhinosinusitis is inflammation of the mucosa of the nose and paranasal sinuses 
characterized by two or more symptoms; one of each should be either nasal discharge 
(anterior or posterior nasal drip), obstruction, blockage, congestion: 
•  +/- facial pain or pressure,  
• +/- smell disturbances 
and either endoscopic signs of: 
•  nasal polyps, and/or 
•  mucopurulent discharge primarily from the middle meatus, and/or 
• edema/mucosal obstruction primarily in the middle meatus 
And/or CT changes that demonstrate mucosal changes within the osteomeatal complex 
or sinuses. 
The disease is divided into acute (i.e. <12 weeks with complete resolution of symptoms) 
and chronic (i.e. >12 weeks without complete resolution of symptom).  
1.1.1. Viral and bacterial rhinosinusitis 
Viral rhinosinusitis should be diagnosed when symptoms or signs of acute rhinosinusitis 
are present for <10 days and the symptoms are not worsening. 
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Bacterial rhinosinusitis is presumed when symptoms or signs of acute rhinosinusitis fail 
to improve within 10 days beyond the onset of upper respiratory symptoms, or the 
symptoms worsen within 10 days after an initial improvement (double worsening) 
 
1.2. Chronic rhinosinusitis 
1.2.1. Classification of chronic rhinosinusitis 
For research purposes, chronic rhinosinusitis is defined as per the clinical definition 
mentioned above. For the purpose of this study, CRS is further divided endoscopically 
into chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without 
nasal polyps (CRSsNP): 
• Chronic rhinosinusitis with nasal polyps: bilateral, endoscopically visualized in the 
middle meatus 
• Chronic rhinosinusitis without nasal polyps: no visible polyps in the middle meatus 
In order to avoid overlap, this definition accepts the idea that there is a spectrum of 
disease in CRS, which includes polypoid changes in the sinus and/or middle meatus but, 
excludes those with polypoid disease presenting in the nasal cavity. In case of past sinus 
surgery, in which the anatomy of the lateral wall has been altered, the presence of polyps 
is defined as bilateral pedunculated lesions >6 months after surgery on endoscopic 
examination. 
1.2.2. Epidemiology of chronic rhinosinusitis 
CRSsNP- due to the heterogeneity of the disorder and the diagnostic imprecision often 
made by clinicians, accurate prevalence of CRS remains speculative. In surveys of 
chronic conditions, CRS was found to affect 15.5% of the total adult population in one 
survey (16) and 16% in the second, defined as having 'sinus trouble' for more than 3 
months in the years before the interview (17). However, the prevalence of doctor-
diagnosed CRS is much lower, a prevalence of 2% (18). The majority of primary care 
physician do not have the equipment necessary to properly diagnose CRS, which leads 
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to overdiagnosis. The prevalence rate is higher in female with a female/male ratio of 6/4 
(16). In a postal questionnaire sent to a random sample of adults aged 15-75 years in 19 
centers in Europe, The Global Allergy and Asthma Network of Excellence (GA2LEN) 
concluded that the overall prevalence of CRS by EP3OS criteria was 10.9% (range 6.9-
27.1) (19). 
CRSwNP- studies rely on nasal endoscopy and/or questionnaires to report on the 
prevalence of nasal polyps. Large nasal polyps can be visualized by anterior rhinoscopy, 
whereas nasal endoscopy is need for smaller nasal polyps. Recently, a panel of French 
experts specializing in ENT elaborated a questionnaire/algorithm with 90% sensitivity and 
specificity (21). For the epidemiologic research, a distinction between asymptomatic nasal 
polyps and symptomatic nasal polyps needs to be made. Asymptomatic polyps may 
transiently be present and hence remain undiagnosed. Symptomatic polyps may remain 
undiagnosed, either because they are missed during anterior rhinoscopy or because 
patients do not seek medical attention for this problem. In comparison, patients who are 
actively seeking medical care for CRSwNP had more extensive nasal polyps with greater 
reduction in peak inspiratory flow and more impairment of the sense of smell. In a 
population-based study done in Sweden, 2.7% of nasal polyps were diagnosed 
endoscopically and were more frequent in males with a ratio of 2.2/1, the elderly (5% at 
60 years or over) and asthmatic (20). Nasal polyps occur in all races and become more 
common with age (uncommon under the age of 20). There was a close linear association 
between the mean age at onset of rhinitis, asthma, NSAID intolerance and nasal polyps. 
1.2.3. Factors associated with CRSsNP and CRSwNP 
1. Ciliary impairment- the ciliary in the body is responsible for the clearance of the 
sinuses and prevention of prolonged inflammation. CRS with long history of 
respiratory infections is common, as expected, in patients with primary disorders 
involving the ciliary function, including Kartagener's syndrome and primary ciliary 
dyskinesia. In Cystic fibrosis (CF), the viscous mucous that is produced causes 
malfunction of the cilia and consequently CRS. Nasal polyps (primarily 
neutrophilic) are present in about 40% of patients with CF (22). Secondary ciliary 
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dyskinesia is found in patients with CRS, and is probably reversible, but restoration 
of function takes some time. 
2. Nasal septal deformation- nasal septal deviation is a common disorder that 
presents in up to 62% of the population, and its role in the pathogenesis of chronic 
sinusitis remains uncertain. Nasal septal deviation may either cause osteomeatal 
obstruction or may interfere with proper airflow and results in sinusitis.  
3. Allergy- articles on CRS have suggested that atopy with allergic inflammation in 
the nose has a role in its development (23,24). The swelling of the nasal mucosa in 
atopic patients may compromise ventilation and even obstruct the sinus ostia, 
leading to mucus retention and infection. A number of studies report the atopic 
markers are more prevalent in CRS patients; 54% of outpatients with CRS had a 
positive skin test (25). Among CRS patients undergoing sinus surgery, the 
prevalence of positive skin testing ranges from 50% to 84%, of which the majority 
(60%) have multiple sensitivities (29,26,27). It was clear that failure to address allergy 
as a contributing factor to CRS diminishes the probability of success of a sinus 
surgery (28). Taking all into account, epidemiologic data show an increased 
prevalence of allergic rhinitis in patients with CRS, but the role of allergy in CRS 
remains unclear. 
4. Asthma- CRSwNP and asthma are frequently associated in the same patients, 
though the inter-relationship is poorly understood (30). The association of CRS with 
asthma was stronger in those reporting both CRS and allergic rhinitis. Wheezing 
and respiratory symptoms are present in 31% and 42% of patients with CRSwNP, 
and asthma is reported by 26% of patients with CRSwNP, compared to 6% of 
control group (31,32). In addition, 7% of patients with asthma has NP (34). NP take 
between 9 to 13 years to develop, but only two years in aspirin-induced asthma 
(34). 10% develop both polyps and asthma simultaneously and the remainder 
develop first polyps and asthma later (35). 
5. Aspirin sensitivity- in patients with aspirin sensitivity 36-96% have CRSwNP (36-42) 
and up to 96% have radiographic changes affecting their paranasal sinuses (43). 
6. Immunocompromised state- development of dysfunctional immunity may occur 
later in life and present with CRS. Congenital immunodeficiencies manifest 
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themselves with symptoms early in life. An unexpectedly high incidence of immune 
dysfunction was found in a retrospective review of patients with refractory sinusitis 
(44). Low Immunoglobulin levels, IgA and IgM titers were found in 18%, 17%, and 
5%, respectively. Common variable immunodeficiency was diagnosed in 10% and 
selective IgA deficiency in 6% of patients. Thus, immunological testing should be 
an integral part of the diagnostic pathway of patients with CRS. 
7. Genetic factors- genetic factors have been shown to have a role such as patients 
with cystic fibrosis and primary ciliary dyskinesia (45) and there is some evidence 
for CRSwNP. Although CRSsNP have been observed in family members, no 
genetic abnormalities have been linked to CRSsNP.  
8. Pregnancy and endocrine state- nasal congestion occurs in approximately one-
fifth of pregnant women (46). The pathogenesis is unclear but several theories have 
been proposed: direct hormonal effect of estrogen, progesterone, and placental 
growth hormone on the nasal mucosa, and indirect effects such as vascular 
changes, may be involved. In addition, thyroid dysfunction has been implicated in 
CRS, but the data is limited. 
9. Local host factors- several anatomic variations have been suggested to contribute 
to the development of CRS such as nasal septal deviation, concha bullosa, and 
uncinate process displacement (47). However, studies have failed to reveal any 
significant correlation between anatomical variation and increased prevalence of 
CRSs or wNP than in a control group (48-50). In spite of the observation that 
sinonasal complaints often resolve after nasal surgery, this does not imply that 
anatomical variation is etiologically involved. Taken all together, so far, there is no 
supportive evidence for a casual association between nasal anatomic variations 
and incidence of CRS. 
10. Biofilms- the surface of nasal polyps is colonized by many biofilm-forming 
pathogenic bacteria that may not be the primary etiologic agent in NP, but a 
contributor significantly adding more inflammation. 
11. Environmental factors- several studies have demonstrated the association of 
smoking with CRS, including exposure to secondhand smoke (51). Other life-style 
related factors are also involved in the chronic inflammatory process. Studies have 
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investigated the relationship between CRS and occupational exposure and have 
concluded that there was an increased prevalence ratio in plant and machinery 
operators and assemblers, elementary occupations, craft workers and the 
unemployed.  
 
1.2.4. Pathogenesis of CRS 
Few hypotheses have been proposed in order to explain the pathophysiology of CRS; the 
first attempt to address it was the "fungal hypothesis", which attributed all CRS to an 
excessive host response to Alternaria fungi (52,53). This was rejected by many investigators 
as originally proposed; however, fungi are still believed to play a role in at least some 
forms of CRS.  
Defects in eicosanoid pathway have also been proposed as a potential cause of CRSwNP 
(54,55); specifically, increased synthesis of pro-inflammatory leukotrienes and decreased 
synthesis of anti-inflammatory prostaglandins (PGE2). This theory is controversial due to 
lack of clinical efficacy with leukotriene pathway inhibitors. 
The microbiology of CRS differs from that of acute rhinosinusitis. In addition to standard 
pathogens; Streptococcus pneumonia, Haemophilus influenza, and Moraxella catarrhalis, 
there is an increased prevalence of S. aureus, Pseudomonas aeruginosa and anaerobic 
bacteria in CRS. The "staphylococcal superantigen hypothesis" suggested that exotoxins 
have a key role in nasal polyposis via effects on multiple cell types (56,57). The net effect 
is Th2 skewing, Treg inhibition, increased eosinophils and mast cell activity, and 
increased tissue damage and remodeling. 
The "immune barrier hypothesis" suggests that dysfunction in the mechanical barrier 
and/or innate immune response of the sinonasal epithelium manifests as CRS. This, 
theoretically, leads to colonization of the mucosa with increased multiple microbial agents, 
heightened barrier damage, and a compensatory adaptive immune response (58,59). 
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Lastly, biofilm formation is said to be facilitated by a defect in the innate immune barrier, 
the mechanism in CRS is unclear, but biofilms on the sinus mucosa have been linked to 
those mediating periodontal disease (60,61). 
Thus, host susceptibility to complex diseases such as CRS involves multiple genetic 
factors but also environmentally-determined epigenetic changes. Ongoing environmental 
stresses confront the susceptible host, which may lead to the development of the 
chronically inflamed state of CRS. 
1.2.5. Diagnosis and Symptomatology of CRS 
Assessment of rhinosinusitis is based on symptoms: 
• Nasal blockage, congestion, or stuffiness; 
• Nasal discharge or postnasal drip, often mucopurulent; 
• Facial pain or pressure, headache, and 
• Reduction or loss of smell. 
In addition, distant and general symptoms occur; distant symptoms are pharyngeal, 
laryngeal and tracheal irritation causing sore throat, dysphonia and cough, whereas 
general symptoms include malaise, drowsiness and fever. The symptoms are principally 
the same in acute and chronic rhinosinusitis with and without polyps, but the symptom 
pattern and intensity may vary. Acute forms of infections have usually more distinct and 
severe symptoms. 
1.2.5.1. Diagnosis of CRS 
Chronic rhinosinusitis, with or without nasal polyps in adults is defined as: 
• Inflammation of the nose and paranasal sinuses characterized by two or more 
symptoms, one of which should be either nasal blockage/obstruction/congestion 
or nasal discharge (anterior/posterior nasal drip) 
• +/- facial pain or pressure  
• +/- reduction or loss of smell 
 For >12 weeks 
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This should be supported by demonstrable disease. Either endoscopic signs of: 
• Nasal polyps, and/or 
• Mucopurulent discharge primarily from middle meatus, and/or 
• Edema/mucosal obstruction primarily in middle meatus 
And/or CT changes:  
• Mucosal changes within osteomeatal complex and/or sinuses. 
It is appropriate that the definition is symptoms based, as it is this that drives patients to 
seek medical care for their CRS. However, the presence of supporting findings is 
important to exclude differential diagnoses. For the majority of patients, diagnosis is made 
in primary care based on symptoms alone. 
1.2.5.2. Symptoms reported in CRS 
In addition to the symptoms listed above, there are several minor symptoms including ear 
pain or pressure, dizziness, halitosis, dental pain, distant and general symptoms including 
nasal, pharyngeal, laryngeal and tracheal irritation, dysphonia and chough, drowsiness, 
malaise and sleep disturbances, presenting in numerous combinations (62,63). 
Nasal obstruction is one of the most common symptoms reported with CRS. Its 
components include: congestion due to dilation of venous sinusoids as a result of 
inflammation and edema, nasal fibrosis and nasal polyposis. Nasal discharge, either 
anterior or posterior, may vary greatly in composition. Patients may report profuse watery 
discharge or thick purulent discharge. 
Facial pain is one of the most variable symptoms, with reported prevalence in patients 
with CRS ranging from 18%-77.9% (64,65). In addition, diagnosis of CRS is associated with 
a 9-fold increased risk of reporting chronic headache compared with the general 
population, and symptoms were significantly improved with surgery and nasal 
corticosteroids treatment (1).  
Olfactory disturbance is common too, due to edema in the area and physical prevention 
odorants reaching the olfactory cleft. In a study of 367 patients with a diagnosis of CRS, 
the presence of polyps was associated with increased risk of hyposmia (OR 2.4 95% CI 
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1.3-4.2, P=0.003) and anosmia (OR 13.2, 95% CI 5.7-30.7, P<0.001) compared with non-
polyp CRS (67). 
Sleep impairment is another common disturbance associated with CRSwNP and 
CRSsNP patients. The key cause is thought to be sleep-disordered breathing that is 
associated with nasal congestion. This can lead to fatigue, daytime somnolence, impaired 
daytime functioning as reflected in lower level of productivity at work or school, and a 
reduced quality of life (68-70). There is a growing amount of evidence that reduction in 
congestion with nasal corticosteroids is associated with improved sleep, reduced daytime 
sleepiness, and enhanced quality of life (71). 
1.2.5.3. Assessment of symptom severity 
Different grading tools can be used to estimate the severity of the overall symptoms of 
CRS; 
• Recorded as severity: no symptom, mild, moderate or severe 
• Recorded as numbers: from 0 to 5 degrees or more 
• Recorded as VAS score on a line giving measurable continuum (1-10). 
Strength, degree and duration should be assessed in each patient. The duration of 
symptoms is evaluated as symptomatic or symptom-free periods (expressed as hours per 
day or as days per week). According to VAS score, a validation study has shown 'mild 
disease' to be defined as a VAS score of 0-3, moderate >3-7, and severe as >7. In 
general, quality of life is affected with scores of 5 or more. 
 
1.2.6. Complications of Chronic rhinosinusitis 
Complication of chronic rhinosinusitis, with or without polyps, are rare and largely due to 
its effects on the surrounding bone. They generally result from an imbalance in the normal 
process of bone resorption, regeneration and remodeling, and are far less common than 
those associated with acute infection and inflammation. In some cases, they may be 
considered as a manifestation of the natural history of the disease. The complications 
may include: 
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1. Mucocele formation 
2. Osteitis 
3. Bone erosion and expansion 
4. Metaplastic bone formation 
5. Optic neuropathy 
There is no evidence the CRS is associated with neoplastic changes, either benign or 
malignant.  
2. Treatment modalities in CRS  
The goal of the treatment in CRS is to reduce mucosal inflammation, to control infections, 
and to restore mucociliary clearance within the sinuses. Eosinophilic inflammation is one 
of the hallmarks of CRS (73), and reducing mucosal eosinophilia is one of the therapeutic 
goals. In the management of CRS no one regimen exists, and treatment should be 
individualized. For those patients with whom allergy, pollution, or mold exposures appear 
to be a risk factor, environmental control is an important modality. Sinus surgery is 
generally reserved for patients who remain symptomatic despite maximal medical 
therapy. In this section, different treatment modalities will be presented, with further focus 
on endoscopic sinus surgery.  
2.1 Corticosteroids 
Topical corticosteroids constitute the first-line therapy in the management of CRS. Long 
term treatment with intranasal steroids has been shown to reduce sinus inflammation and 
nasal polyp size and improve associated symptoms (74-76). Oral steroids are used in the 
treatment of CRS with nasal polyps and in the cases of severe CRS when rapid 
symptomatic improvement is needed (75,77). Topical and systemic steroids reduce 
eosinophil chemotaxis and increase their apoptosis, they also decrease white blood cell 
migration, production of inflammatory mediators, antibody production, histamine release, 
and swelling (78).  
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• Topical nasal steroids- several studies have demonstrated that topical steroids are 
beneficial in the treatment of CRS, especially when small to medium-sized polyps 
are involved and for rhinitis symptoms (78,79). In addition, corticosteroids have been 
shown to delay recurrence of polyps after surgery (80). Common side effects with 
intranasal steroid use include nasal irritation, mucosal bleeding, and crusting (76,77).  
• Systemic steroids- oral steroids have been effective in treating allergic rhinitis, 
providing rapid relief of facial pain or pressure, nasal blockage by reducing 
mucosal edema, especially in patients with CRSwNP (81,82). In a study of 25 
patients with CRSwNP with massive polyps, treatment with high-dose oral 
prednisolone was associated with both subjective and objective improvement and 
involution of nasal polyps (83). 
The daily usage of topical nasal steroids appears to be associated with minimal risks, 
however, long-term systemic steroids is associated with significant side effects (76,77). 
Therefore, a tapered regimen of oral steroid is given during severe flare-ups of CRS or in 
the postoperative period after sinus surgery. 
2.2 Nasal irrigation 
Saline nasal irrigation has been advocated as an adjunct therapy for CRS. The procedure 
promotes mucociliary clearance by flushing out mucus, crusts, and irritants. In addition, 
cavity irrigation brings enhancement of ciliary activity, removal of antigen, biofilm, or 
inflammatory mediators, and a protective role on the sinonasal mucosa (84). Nasal 
irrigation is also useful after endoscopic sinus surgery to clear crusts and mucus that 
appear postoperatively. Hypertonic saline is often used and have been described to have 
a beneficial role in decongesting the nose through an osmotic mechanism (85). 
Budesonide have been added too as an adjuvant method of treating sinus inflammation. 
Its use after sinus surgery decreases mucosal inflammation, shortening the stage of 
epithelization and accelerates the recovery of the mucosa (86). Topical antibiotics and 
topical steroids have been added too (87). 
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2.3. Antibiotics  
Most experts agree the antimicrobials for the treatment of CRS should provide broad-
spectrum coverage. Commonly used antibiotics include amoxicillin-clavulanate, 
ciprofloxacin or levofloxacin, clindamycin, and trimethoprim/sulfamethoxazole. The 
bacterial flora cultured from purulence in cases of CRS tend to demonstrate increased 
antibiotic resistance. Antibiotics are typically used for 3-4 weeks in order to maximize the 
anti-inflammatory effect, to lower bacterial loads, and to treat acute exacerbations of CRS. 
The potential association between fungi and inflammation in CRS has generated interest 
in the use of antifungal agents too. 
2.4. Other medical treatments 
No randomized clinical trials for the treatment of CRS were found regarding 
antihistamines, mucolytics and expectorants, homeopathic remedies, proton pump 
inhibitors, and surfactants including baby shampoo or nasal decongestants. These 
treatment modalities are not recommended, but may provide temporary symptomatic 
relief. 
2.5. Surgical Modalities 
If medical treatments have not been successful in improving sinus symptoms, endoscopic 
sinus surgery may be helpful. The main goal of sinus surgery is to improve the drainage 
pathway of the sinuses. By widening the natural drainage pathway of the unhealthy 
sinuses, sinus infections should be reduced. Patients with obstruction or blockage of their 
sinuses due to their sinus anatomy do very well with sinus surgery. Many patients also 
have a problem with inflammation of the sinus lining (mucous membrane). Patients with 
mucous membrane disease also usually improve with sinus surgery because creating the 
larger sinus opening will allow better sinus drainage and more rinses/medication to get 
into the sinuses and help treat the diseased lining. One of the most important benefits of 
surgery is the ability to deliver medications (sprays, rinses, nebulized drugs) to the lining 
of the sinuses after they have been opened. Therefore, sinus surgery is done in addition 
to, and is not a replacement for, proper medical treatment of the sinuses. It is important 
to note that the patients who have diseased mucous membranes or a form of nasal 
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polyps, no amount of surgery can change this fact. For many patients, surgery may not 
be a cure for sinusitis, but it is one of the many critical steps in managing sinus disease. 
Surgical interventions used for CRS primarily involve open surgery, which is aimed at 
mucosal stripping within the maxillary or frontal sinuses, or ethmoidectomy performed 
with limited visualization. Such surgery has almost completely been replaced by 
endoscopic sinus surgery (ESS). ESS is associated with significantly lower morbidity and 
higher success rates than previous surgical approaches (88). 
ESS may be done under local or general anesthesia. Local anesthesia involves numbing 
the nasal/sinus cavity, but the patient remains awake (or lightly sedated). General 
anesthesia means that the patient goes to sleep with anesthesia for the surgery. ESS 
involves the use of a small telescope (nasal endoscope) that is inserted through the nostril 
to view the nose and sinuses. The goal of the surgery is to identify the narrow channels 
that connect the sinuses to the nose, enlarge these narrow openings/channels, and 
improve the drainage from the sinuses into the nose. Most people have four sinuses on 
each side of their face, for a total of eight sinuses. These are the maxillary, ethmoid, 
sphenoid, and frontal sinuses. The maxillary sinuses are in the cheek, the ethmoid 
sinuses are between the eyes, the sphenoid sinuses are almost exactly in the center of 
the head, and the frontal sinuses are in the forehead. It is possible that one may not have 
all of these sinuses due to differences from person to person, or one’s sinus may have 
already been opened by previous surgery. Sinusitis may affect some or all of the sinuses.  
 
2.5.1. Surgery for CRSwNP 
Twenty percent of CRS patients have nasal polyps. From a clinical, radiological, and 
histological point of view the mucosal inflammatory response is more florid in CRS 
patients with nasal polyps than in those without, and the relapse rate after surgery for 
nasal polyps is much higher (72). Surgical intervention in the treatment of nasal polyps is 
preserved for patients who fail to improve after a trial of maximal medical therapy. 
Functional Endoscopic Sinus Surgery (FESS) involves the clearance of polyps and 
polypoid mucosa and opening of the sinus ostia. Removal of the inflammatory tissue and 
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the reduction in load of antigens mediating this inflammation, as well as the improvement 
of the sinus ventilation and mucociliary clearance, are the probable mechanisms whereby 
FESS improves symptoms in CRSwNP. 
The outcome of sinus polypoid surgery is influenced by whether the polyps are idiopathic 
or related to an underlying mucosal condition such as aspirin-induced respiratory disease, 
cystic fibrosis, or primary ciliary dyskinesia. However, in both idiopathic and secondary 
cases, the long-term efficacy of ESS is dependent on the regimen of medical treatment 
prescribed postoperatively and the subsequent compliance to this regimen. 
 
2.5.2. Efficacy of surgery for nasal polyps 
 Endoscopic sinus surgery for nasal polyposis has been generally reported to be a safe 
and effective procedure. A number of series have demonstrated that sinus surgery in 
patients with nasal polyps can result in a prolonged reduction of nasal symptoms and an 
improvement in quality of life. Dalziel et al. evaluated 33 articles published between 1978 
and 2001 (89). The review included three studies comparing FESS with Caldwell-Luc or 
other endonasal procedures (n=240), three nonrandomized studies comparing different 
surgical approaches (n=2,699) and 27 case series (n=8,208). Seven studies included only 
patients with polyps and 26 had CRS with and without polyps. Patients judged their 
symptoms to be 'improved' or 'greatly improved' in 75 to 95% of cases. The percentage 
of overall complications was low (1.4% for FESS compared to 0.8% for traditional 
procedures). The implications of this review are that FESS is safe and effective treatment 
for the great majority of patients.  
 
2.5.3. Efficacy of surgery for nasal polyps compared to CRSsNP 
The efficacy of FESS in patients with nasal polyps is at least as great as in patients with 
CRSsNP. There is some evidence that a significantly higher rate of recurrent surgery is 
required in patients with nasal polyposis than those without polyps (90). Despite the 
increased rates of revision, patients with polyps may have more improvement following 
sinus surgery than CRSsNP patients (92). In one large series, FESS was performed in 251 
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patients with medically refractory CRS, 86 with polyps and 165 without, and the patients 
were followed for at least 12-months. Symptoms scores improved significantly (p<0.001). 
There were no major differences between the groups except in oropharyngeal symptoms, 
which were improved more in the non-polyp patients (91). 
 
2.5.4. Efficacy of surgery for nasal polyps compared to medical therapy 
As surgery for nasal polyposis is usually not considered until medical therapy has failed 
to provide adequate relief, a clinically relevant comparison of relative efficacies between 
surgical and medical treatments is difficult to make since the patient populations in whom 
these treatment modalities are indicated are different.  
 
However, if untreated patients are randomized into either a medical treatment or a 
surgical one comparisons of the relative efficacies of these approaches can be made. 
In a randomized controlled trial comparing the effect of medical and surgical treatment of 
CRS on quality of life, 90 patients were evaluated before and after 6 and 12 months of 
follow up after either medical or surgical therapy (93).  Both medical and surgical treatment 
of CRS improved most of the domains of SNOT-20 (sinonasal outcome test) and SF-36 
(short form health survey) (p<0.05), with no significant difference being found between 
the two groups (p>0.05). Nasal symptoms and polyp size improved after both medical 
and surgical treatment at 6 and 12 months. These results suggest that both medical and 
surgical treatment can lead to similar effects in improving quality of life. 
 
Although this study provides an interesting insight into the relative efficacies of both 
modalities in unselected patients, it doesn’t reflect currently accepted practice guidelines 
in which surgery is preformed in medically refractory patients. In other words, the efficacy 
of FESS is equivalent to the efficacy of medical therapy, which includes systemic 
corticosteroids treatment, in CRSwNP patients randomized to receive one or other 
treatment. 
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2.5.5 Complications of sinus surgery 
The list of the complications in this paragraph is not intended to be all-inclusive, but rather 
to highlight some of the more common complications the are worth mentioning (94); 
• Bleeding: It is normal to have some degree of bleeding after surgery on the nasal 
septum or turbinates. Rarely does this require additional intervention and 
extremely rarely does it require blood transfusion. Non-steroidal anti-inflammatory 
and certain over-the-counter supplements such as vitamin E and gingko can 
increase the risk of bleeding, so patients should consult with their physicians 
regarding the use of any medications before or after surgery. Postoperative 
bleeding most commonly occurs within the first 24 hours of the procedure, but can 
be delayed days or even weeks. In case of septal hematoma removal of the 
hematoma is necessary, and the development of scar tissue or even nasal 
collapse could occur. 
• Infection: The most common reason to undergo sinus surgery is a chronic sinus 
infection that does not resolve with medications. The patient with sinusitis is 
therefore at risk of developing certain other infections in this area (abscesses, 
meningitis, etc.) from sinus surgery, although it important to recognize that this is 
also a complication of not undergoing surgery for a refractory chronic sinus 
infection. 
• Impaired sense of taste or smell: The sense of smell usually improves after the 
procedure because airflow is restored, although in sporadic cases it could worsen 
depending on the extent of swelling, infection, or allergy. This impairment is often 
temporary, but can be prolonged. 
• Voice changes: One of the functions of the sinuses is to affect resonance, so 
vocal professionals should be aware of potential changes in their voice after 
sinus surgery. 
• Nasal obstruction: Surgery typically improves airflow, but in some patients, it may 
not improve or rarely may worsen. Small scar bands may occur in the nose and 
require removal by the surgeon at postoperative visits. 
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• Numbness: Numbness of the front upper teeth, lip or nose may occur after 
surgery, but it is usually self-limiting and does not require further treatment. 
• Pain and dryness: turbinates are “swell bodies” that are present along the 
sidewall of the nasal cavity. They often become too enlarged and their size is 
physically reduced during nasal surgeries, and this often improves symptoms 
such as nasal congestion of obstruction. However, in some patients this may 
leave them with the sensation of being overly dry or even cause chronic pain; a 
very rare, but severe form of this is referred to as “empty nose syndrome.” 
• Intraorbital complications: The eye is situated directly next to several of the 
paranasal sinuses and is separated from them by a thin layer of bone. Because of 
the close proximity, in rare cases, bleeding may occur into the orbit, requiring 
treatment at the time of the initial surgery. Visual loss and blindness have been 
reported, but are extremely rare. Another uncommon problem is damage to the 
muscles that move the eye, leading to double vision, which can be temporary or 
permanent. In certain circumstances, there may be a change in the function of the 
tear ducts causing excessive tearing. Since the eye is in close proximity to the 
sinuses, a major orbital complication or blindness could possibly occur even 
without surgery for patients with severe or refractory CRS. 
• Intracranial complications: The floor of the brain is where the septum attaches to 
the roof of the nose. If this thin bony layer is fractured, CSF can leak into the nose. 
While rare, this is likely to be identified and repaired in the operating room at the 
time of the primary surgery. In rare cases, this could lead to infection of the 
meninges, bleeding into the brain, or the need for further intracranial surgeries. 
2.5.6. Recovery 
Some nasal packing may be used during surgery, although in general, this is less 
common than it was in the past. The operating surgeon will determine whether nasal 
packing will be used. The recovery period will vary depending on the surgery performed 
and the individual patient. Many people do not have much pain after sinus surgery, but 
every patient is different. Depending on the extent of the surgery, one may be prescribed 
stronger pain medicine. Generally, postoperative discomfort, congestion, and drainage 
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should improve after the first few days, with mild symptoms sometimes lingering several 
weeks after the surgery. Because sinus surgery is just one step in treating sinus disease, 
the surgeon may also place you on medications that can include saline rinses, nasal 
steroid sprays, and possibly antibiotics. 
3. Aim 
The aim of this study is to investigate the incidence of different sinonasal diagnoses and 
their distribution according to demographics, risk factor, and type of endoscopic surgical 
procedures which were performed to treat sinonasal diseases, in the Department of ORL 
HNS Sisters of Charity University Hospital, during the period of January 1 to December 
31 of the year 2016. 
4. Material and Methods 
This study is a randomized retrospective study of a surgical database, from the ENT 
department at Sisters of Charity hospital in Zagreb, of the characteristics of 189 patients 
who were diagnosed with CRS and who underwent ESS in 2016. The data collected 
included disease phenotype, age, sex, sinuses involved, previous operations, and risk 
factor exposure; septal deformation, allergy, asthma, cystic fibrosis, and smoking.  
The patient files were collected from the archive room. Out of 246 patients with CRS who 
were admitted to the ENT department in 2016, a total of 189 patients underwent 
endoscopic sinus surgery in a period of a year. This study was done to review the 
demographic characteristics of those patients who had ESS and analyze them. For views 
and statistical calculations, Microsoft Excel Office was used. 
5. Results 
A total of 189 patients were reviewed, 115 males (60.8%) and 74 females (39.2%), male 
to female ratio is 1.55:1. 
In this study 13 patients are in the age group of <20 years (6.8%), followed by 28 in the 
age group of 19-30 (14.8%), 54 patients are in the age group of 31-45 (28.5%), 57 patients 
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67% of the participants are diagnosed with CRSwNP while 31% are diagnosed with 
CRSsNP. 4 patients were diagnosed with CRS with tumor (2%). An interesting fact is that 
74 patients with CRSwNP are affected bilaterally and 66 unilaterally, and 10 patients with 
CRSsNP are affected bilaterally while most of CRSsNP patients, 44, are affected 
unilaterally. 
Different variables were taken from the participants and they include demographic view 
and risk factor exposure as well as previous endoscopic sinus surgeries performed. 
Out of the 131 patients with CRSwNP 85 are males and 46 are females, in the CRSsNP 
group 58 participants, 30 patients are males and 28 are females. The mean age for 
CRSwNP group and for CRSsNP group is 49.2 and 38.7 respectively. 4 Patients with 
CRS with tumor are counted in the table as CRSwNP (see table 1). 
 
25.2% (33) of patients diagnosed with CRSwNP had septal deformation, 21 (16%) of 
them had it operated on the same day with the ESS. In the CRSsNP group, 55% (32) had 
septal deformation and 23 (40%) of them had it operated on the same day with the ESS. 
1 patient with CRSwNP and 1 patient with CRSsNP had septal reconstruction operation 
done on different occasions (table 1). 
 
A view on the risk factors given shows that 45 patients (34.3%) with CRSwNP and 18 
patients (31%) with CRSsNP have allergy, 27(20.6%) of CRSwNP patients have asthma 
while 2 (3.4%) of CRSsNP patients have asthma. Aspirin sensitivity is found in 8 patients 
with CRSwNP (6.1%) and 2 patients (1.5%) with CRSwNP have Cystic Fibrosis, both 
aged 9. 30 patients with CRSwNP (22.9%) and 19 patients with CRSsNP (32.7%) are 
smokers (table 1). 
Variables CRSwNP CRSsNP 
Sex M/F 85/46 30/28 
Mean Age 49.2 38.7 
Septal deformation 33 (25.2%) 32 (55%) 
Allergy 45 (34.3%) 18 (31%) 
Asthma 27 (20.6%) 2 (3.4%) 
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Table 1- 
Characteristics of participants in relation to main disease phenotype. 
CRS is a chronic condition that, in many cases and especially for patients with nasal 
polyps, requires more than one operation during the course of the disease. 46 patients 
(35%) with CRSwNP and 10 patients (17%) with CRSsNP have had an ESS procedure 
before. 35 patients had undergone one ESS procedure before; 28 patients (80%) with 
CRSwNP and 7 (20%) patients. 8 patients with CRSwNP and 1 patient with CRSsNP had 
two procedures. 8 patients with CRSwNP had 3-5 previous operations and 4 patients had 
more than 5 operations, the highest amount of procedures per participant was 21 (table 
2). 
 
 
Number of previous ESS Number of patients 
One 35 
Two 9 
Three- five 8 
More than five 4 
 
Table 2- Amount of previous endoscopic sinus surgery per participant 
 
Sinuses are formed in childhood by the nasal cavity eroding into surrounding bone. As 
they are outgrowths of the nasal cavity, they all drain back into it. Openings to the 
paranasal sinuses are found on the roof and lateral walls of the nasal cavity. The inner 
surface is lined by a respiratory mucosa. CRS with or without polyps is a disease that is 
very variable among patients with different sinuses involved and, in many cases, more 
than one sinus or even all of the sinuses can be involved (graph 3). 
 
 
 
Aspirin sensitivity 8 (6.1%) 0 
Smoking 30 (22.9%) 19 (32.7%) 
Cystic fibrosis 2 (1.5%) 0 
Previous ESS 46 (35.1%) 10 (17%) 
ESS+Septal reconstruction  21 (16%) 23 (40%) 
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CRSwNP is frequently characterized by hyposmia. Nasal polyps (CRSwNP) are defined 
as pedunculated lesions as opposed to cobblestoned mucosa, endoscopically visualized 
in middle meatus (96). CRSwNP reportedly occurs in 0.5% to 4.3% of the population (97). 
The prevalence tends to increase with age and the disease occurs more often in men. In 
our study, in the CRSsNP group, out of the participants who underwent ESS there were 
30 males and 28 females while in the CRSwNP there were 85 males and 46 females, a 
ratio of 2:1, higher than in the CRSsNP group of participants. Most of the patients were 
in age groups 30-60 (111 patients, 58%), the mean age for CRSwNP and CRSsNP was 
49.2 and 38.7 respectively. For comparison, a study that was done in patients with CRS 
who underwent ESS (142) consisted of 38 patients with CRSsNP with a mean age of 
31.2 years and male female ratio of 9:10.  52 patients with CRSwNP with a mean age of 
37.5 years and male female ratio of 9:17. Another study included 116 patients with 
CRSwNP, 75 (64.7%) were male and 41 (35.3%) were female patients, male to female 
ratio of 1.8:1. Mean age of presentation in males was 39.1 years and that of females was 
36.7 years. As in our study the mean age for CRSwNP is older than for CRSsNP, the 
male to female ratio is variable. The rates of CRSwNP to CRSsNP in our study (67% 
CRSwNP and 31% CRSsNP) match the results in the largest study of its kind (92), the UK 
National Sinonasal audit was a multi-center prospective cohort study from 87 hospitals 
and 298 UK Consultant Otorhinolaryngologists about patients who underwent ESS, in 
which 70 % of the 3128 patients had nasal polyps, and 30 % didn’t have nasal polyps. 
ESS has been found to have a beneficial impact on the sinonasal outcome in patients of 
chronic rhinosinusitis with 85–93% of patients reporting relief from symptoms and 
improved QOL (98,99) In spite of the success in CRS and the use of ESS commonly for 
CRSwNP, it was found CRSwNP patients to have refractory disease with a tendency to 
recur even after prolonged medication and surgical intervention;  Darsum et al. have 
observed a lower success rate in NP group (54.3%) as compared to CRS group (93.7%) 
after ESS (99). In the UK national sinonasal audit mentioned above (92), 52 % had previous 
sinonasal surgery, compared with 34 % in those without nasal polyps. In our study, 56 
patients in total had at least one previous ESS, 46 of them are patients with CRSwNP in 
comparison to 10 patients with CRSsNP. In addition, 21 participants had more than one 
previous ESS, 20 
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Any anatomical, physiological or pathological features which in a way or other obstructs 
free drainage from the sinuses, permits the stasis of secretion and thus predisposes to 
infection.  Many factors have been described as playing a role in the development of 
chronic sinusitis. These include allergy, asthma, dental disease, nasal polyps, 
immunodeficiency, mucociliary disorders, trauma, medications, surgery, noxious 
chemicals and micro-organisms (viral, bacterial and fungal), anatomic abnormalities such 
as a septal deviation, concha bullosa, septal spur or paradoxical turbinate (95) 
A proposed mechanism by which allergy leads to the development of sinusitis is allergy-
induced mucosal inflammation leading to ostial obstruction. Ostial obstruction in turn may 
promote an environment for bacterial overgrowth and/or perpetuation of inflammation. 
Certainly, in the nasal passages, IgE-mediated degranulation of mast cells leads to 
mucosal edema. Whether this same process occurs in the paranasal sinuses is less clear. 
Impaired ciliary function and mucociliary clearance are often observed in CRSsNP. Cilia 
from patients with CRSsNP have demonstrated a blunted response to substances that 
typically stimulate cilia in healthy controls (100,101). 
 Allergy is possibly more prevalent in CRSwNP compared with CRSsNP. As far as an 
association between allergy and CRSwNP, several studies have demonstrated an 
increased prevalence for perennial allergies in patients with CRSwNP compared with 
controls, with reports varying between 45% to 77.4% (102-106). Additionally, 2 studies 
showed a strong association between perennial allergies and CRSwNP with odds ratios 
of 2.69 and 6.0 described. (102,106). In our study, 34.3% (45) patients with CRSwNP and 
31% (18) patients with CRSsNP have allergy. Taking all into account, it is difficult to come 
to any conclusions on the role of allergy in CRSsNP and in CRSwNP patients, the 
prevalence of allergy in patients with CRSwNP is higher than that of the general 
population and may be higher than in CRSsNP. 
There is a high prevalence of CRS among patients with asthma, and the presence of CRS 
is associated with poor asthma outcomes, especially with CRSwNP (107-110). Moreover, 
comorbid asthma is an important risk factor for resistance to therapeutic interventions for 
CRS, such as endoscopic sinus surgery (111,112). Compared to patients who do not have 
asthma, patients with asthma and CRS have poorer outcomes, less quality of life 
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improvement, and a higher rate of revision surgery after ESS (115,116). In our study, 20.6% 
(27) of patients with CRSwNP have asthma, while in the CRSsNP group of patients, 3.4% 
(2) are diagnosed with asthma. In sense of pathogenesis, in CRSwNP, there is an 
increase in the Th2 cytokines like IL-4, IL-5 and IL-13 (113,114) and the intensity of 
eosinophils in the tissues of these patients is markedly increased in the presence of co-
existing asthma or positive allergy skin tests. Based on family studies, it has been 
estimated that CRS exhibits a heritability of 13% to 53% (117-119) with highest heritability 
seen in the asthma and aspirin intolerance (118). Asthma, a disease with an even higher 
heritability, has been reported to occur in 20% to 31.9% of CRS subjects (120,121). In our 
study, 8 patients with CRSwNP (6.1%) had aspirin intolerance in comparison to 0 patients 
from the CRSsNP group. 
Mucociliary clearance is grossly impaired in CF because of alterations in the 
transepithelial passage of anions (chloride and bicarbonate) caused by genetic mutations 
in the CFTR (122). Disturbances in anion transport result in viscous secretions that obstruct 
sinus ostia and create hypoxic conditions with increased edema, secondary ciliary 
dyskinesia, and subsequent bacterial overgrowth (123,124). Patients with classic CF have a 
high incidence of CRS approaching 100%. CF patients have a high incidence of nasal 
polyposis associated with CRS (7–48%) (125). in our study 2 CF patients aged 9 diagnosed 
with CRSwNP had undergone ESS. 
Tobacco smoke exposure is considered an important negative prognostic factor for CRS, 
and smoking has been demonstrated to increase the risk for CRS (128).  There is clear 
evidence in the literature that tobacco smoke, either through active smoking or passive 
exposure to secondhand smoke, contributes to CRS (129). The prevalence of CRS has 
been reported to be higher in smokers (130,131). 22.9% of CRSwNP patients are smokers 
and 32.7% of CRSsNP patients. In our study we did not follow the outcome of our patients 
but the impact of tobacco smoke exposure on ESS outcomes has been investigated and 
smokers have a less favorable response to ESS (132,133). It has been reported that both 
secondhand smoke-sensitive and –nonsensitive individuals had increased symptoms of 
rhinorrhea, nasal congestion, and headache following sidestream smoke exposure (134). 
However, there is little evidence of the role of tobacco smoke as a causal agent of CRS. 
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A total of 65 patients (34%) with CRS had septal deformation (33 -CRSwNP, 32-
CRSsNP). There are three theories explaining the relation between the nasal septal 
deviation and chronic rhinosinusitis. The first of these is the mechanical theory, which 
states that secretions accumulates in the sinus as a result of narrowing of the ostiomeatal 
complex and thus infections ensue in the retained secretions and causes chronic 
rhinosinusitis. The second theory is the aerodynamic theory. According to this theory, the 
mucociliary activity decreases following the nasal flow rate increase and mucosal dryness 
in relation with the nasal septal deviation and consequently, chronic rhinosinusitis 
develops. The third theory is the Bachert’s pressure theory. According to this theory, 
deviation of the posterior nasal septum causes chronic rhinosinusitis by creating pressure 
and air flow changes within the maxillary sinuses (95,126). 
In our study we presented the sinuses that were operated in each patient, ethmoid sinus 
alone and maxillary sinus alone were most commonly involved with 17% and 13% of 
operations respectively. Operation on both sinuses together was found in 19% of cases.  
We have observed that involvement of sphenoid and frontal sinuses alone was quite rare, 
2% each. However, operation on multiple sinuses/all sinuses (pansinusitis) was found in 
40% of patients. 
Lastly, most patients with CRS have involvement of more than one sinus. In a study done 
in Karnataka, India (127), they calculated the frequency of involvement of paranasal 
sinuses in CRS patients, Maxillary sinus (99%) was the most commonly involved sinus, 
followed by Anterior Ethmoids (89%), Frontal (64%), Posterior Ethmoids (61%) 
and Sphenoid sinus (31%).  
 
7. Conclusion 
-We concluded that most patients who needed surgery had the CRSwNP phenotype, and 
the tendency for refractory disease and revision of surgery was almost exclusively 
associated with CRSwNP patients. 
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-Risk factors; mean age, male gender, allergy, asthma, aspirin sensitivity, CF, and 
previous ESS rates were higher for patients diagnosed with CRSwNP.  
-Male patients with CRSwNP were significantly more often operated.  
-Most predominant age groups were 31-45 and 46-60. Children were rarely operated. 
-Sinuses most commonly involved in CRS are maxillary and ethmoid as a single-sinus 
involvement, but most of the patients who needed surgery had involvement of multiple 
sinuses. Frontal and sphenoid were the least involved. 
 -Moreover, we concluded septal deviation to be a major associating factor for CRS with 
34% of our patients having septal deviation and 16% were operated on the same occasion 
together with the endoscopic sinus procedure. 
Chronic rhinosinusitis is most common rhinological problem encountered worldwide 
which has greater propensity to cause morbidity. This study brings light on the various 
characteristics implicated in causation or association with CRS patients who were in 
need of a surgical treatment. Although it recently has been established that chronic 
rhinosinusitis is a frequent disease in Europe and the US, data from other continents are 
scarce, but are needed to recognize race differences and factors associated with CRS 
prevalence. Factors predisposing to CRS, such as smoking need to be confirmed and 
others identified. The tools to screen for CRS in epidemiological studies need to be further 
developed, specifically in terms of differentiation between CRS types. This goes in parallel 
with the need to “pheno- and endotype” CRS, most likely involving tissue biomarkers and 
their surrogates in serum and secretion. Again, these studies need to be performed in 
various areas of the world, as inflammation in CRS may considerably vary from region to 
region, and also may show alterations over time. 
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